Descrizione del progetto
Terapia combinatoria per il trattamento delle malattie infiammatorie immuno-mediate
Le malattie infiammatorie immuno-mediate (IMID, Immune-Mediated Inflammatory Diseases) rappresentano un gruppo di disturbi autoimmuni eterogenei con alcune caratteristiche comuni a livello molecolare e cellulare; esse comprendono l’artrite reumatoide, la psoriasi, la malattia di Crohn, la colite ulcerosa e il lupus eritematoso sistemico. Il progetto DocTIS, finanziato dall’UE, mira a migliorare drasticamente la prognosi delle IMID identificando le terapie combinatorie efficaci e quali gruppi di pazienti mostrano una risposta ottimale al trattamento. Utilizzando campioni provenienti da biobanche specializzate in IMID, saranno ottenuti nuovi dati molecolari utilizzando tecnologie avanzate ad alto rendimento. Saranno applicati metodi di biologia dei sistemi per modellare le risposte a terapie mirate e prevedere quali combinazioni di farmaci agiranno sinergicamente. Per fornire una prova del concetto, dopo la fase preclinica, sarà testata la terapia combinatoria ottimale in un gruppo di pazienti con un profilo biomarcatore positivo.
Obiettivo
Immune-Mediated Inflammatory Diseases (IMIDs) are a group of common autoimmune diseases that include clinically heterogeneous disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus. Despite their clinical heterogeneity, IMIDs share a significant number of features at the molecular and cellular levels. Recently developed therapies targeting common key molecules of the immune system like anti-TNF agents, have collectively resulted in a significant improvement in the management of IMIDs. Still, the complete control of the chronic inflammatory process is rarely attained, and too many patients experience a poor response, if at all. This inefficacy has become a major economic burden and severely impacts on the wellbeing of many European citizens. The DocTIS projects aims to profoundly change this trend by identifying highly effective combinatorial therapies as well as the group of patients where this response will be optimal. Using the standardized samples from one of the world’s largest biobanks specialized in IMIDs, new molecular data will be generated using advanced high-throughput technologies including single cell RNA-seq. Systems biology methods will be applied to this unique clinical and molecular data to model the response to targeted therapies and predict what drug combinations will act synergistically and on which types of patients. After validation in a preclinical stage, the optimal combinatorial therapy will be tested in a group of patients with a positive biomarker profile. Using a basket trial, a new type of clinical trial design that incorporates molecular marker information, the DocTIS project will provide proof of concept of the utility of combinatorial therapy and personalized medicine for the effective control of disease activity in IMIDs.
Campo scientifico
- medical and health sciencesclinical medicinerheumatology
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health scienceshealth sciencespersonalized medicine
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2019-Two-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
08035 Barcelona
Spagna